Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HSTM heads into its October 19 Q3 report with the most consequential ownership development in years sitting fresh on the register.
A Schedule 13D activist filing from WJRJJ Ventures, LLC landed on September 21, declaring a 9.6% stake of 2.8 million shares. A 13D is not a passive disclosure; it signals intent to engage with management or push for change. That makes it the single most newsworthy fact about this stock right now, and it arrived just weeks before the print. The activist disclosure note applies: stakes are as last disclosed around the 5% threshold, and a holder dropping below 5% may exit without a further filing. Willis Johnson also appears in the institutional register at the same 2.8 million share figure, reported on September 14, reinforcing the size of this new position. BlackRock has been adding as well, lifting its holding to 13.3% of shares.
Options positioning paints a notably bullish picture. The put/call ratio has compressed to 0.05, well below its 20-day average of 0.07 and around one standard deviation below that mean. That is among the lowest defensive demand readings of the past year; call activity is dominant. The stock itself is up 11.7% over the past month to $33.13, though it slipped 1.8% on October 16. Peers across health-care technology had a strong session, with , and all rising 5% or more on the day, making HSTM's single-session dip look like a divergence rather than a sector move.
The analyst consensus remains cautious despite the price run. All four covering analysts carry Hold ratings, with a mean target of $35. Freedom Capital Markets initiated coverage October 13 at Hold with a $36 target, the most recent action. Canaccord Genuity has raised its target twice this year but has stayed at Hold throughout a period when the stock has outrun the Street's conviction. The tension is straightforward: bulls point to a 12% one-month advance, a strong EPS surprise track record ranking in the 80th percentile, and the signal that a 9.6% activist holder sees value not yet in the price. Bears note a P/E near 40x, an EV/EBITDA around 11.7x, and a consensus that has consistently underestimated how far the stock could run without upgrading.
Short positioning carries little drama heading into the event. At 4.3% of the float, short interest has fallen roughly 7% over the past week. Borrowing costs are low at 0.42% and availability is ample, with shares available to borrow running at more than 18 times the existing short interest. There is no squeeze setup, and no evidence that the recent price gains have been short-cover driven.
The print will test whether the operational momentum that drew an activist onto the register translates into numbers that close the gap between where the stock trades and where a still-cautious analyst community is prepared to follow it.
See the live data behind this article on ORTEX.
Open HSTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
